BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 6128216)

  • 1. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Oct; 24(4):267-303. PubMed ID: 6128216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
    Helman CA; Tim LO
    Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
    Langtry HD; Grant SM; Goa KL
    Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranitidine: a new H2-receptor antagonist.
    Berner BD; Conner CS; Sawyer DR; Siepler JK
    Clin Pharm; 1982; 1(6):499-509. PubMed ID: 6309467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranitidine v. cimetidine in peptic ulcer.
    Drug Ther Bull; 1982 Jul; 20(15):57-9. PubMed ID: 6128213
    [No Abstract]   [Full Text] [Related]  

  • 8. The treatment of "cimetidine resistant" peptic ulcers by ranitidine hydrochloride: a new histamine H2-receptor antagonist.
    Mohammed R; Mitchell KG; Mackay C
    Curr Med Res Opin; 1981; 7(8):523-5. PubMed ID: 6118237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Price AH; Brogden RN
    Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
    Simon B; Müller P; Dammann HG
    Wien Med Wochenschr; 1982 May; 132(10):223-8. PubMed ID: 6126962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ranitidine, a new histamine H2 receptor antagonist. First experimental and clinical data].
    Simon B; Dammann HG; Müller P; Kather H
    Minerva Med; 1981 Oct; 72(40):2657-61. PubMed ID: 6117040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients.
    Konturek SJ; Obtułowicz W; Kwiecień N; Kopp B; Oleksy J
    Scand J Gastroenterol Suppl; 1981 Jun; 69():91-9. PubMed ID: 6119789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ranitidine and cimetidine in the inhibition of histamine, sham-feeding, and meal-induced gastric secretion in duodenal ulcer patients.
    Konturek SJ; Obtulowicz W; Kwiecien N; Sito E; Mikos E; Oleksy J
    Gut; 1980 Mar; 21(3):181-6. PubMed ID: 6105116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of roxatidine acetate: a review.
    Dammann HG; de Looze SM; Bender W; Labs R
    Scand J Gastroenterol Suppl; 1988; 146():121-34. PubMed ID: 2906456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of a new histamine H2-receptor antagonist, ranitidine, on experimental acute gastric and duodenal ulcers (author's transl)].
    Okabe S; Kunimi H; Ohtsuki H
    Nihon Yakurigaku Zasshi; 1981 Apr; 77(4):397-406. PubMed ID: 6116654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranitidine--pharmacology and clinical use.
    Dawson J; Richards DA; Stables R; Dixon GT; Cockel R
    J Clin Hosp Pharm; 1983 Mar; 8(1):1-13. PubMed ID: 6132928
    [No Abstract]   [Full Text] [Related]  

  • 19. H2 receptor antagonists.
    Siepler JK; Campagna KD; Donahue PE; Bombeck CT
    Am J Hosp Pharm; 1978 Feb; 35(2):141-5. PubMed ID: 24338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy and prevention of duodenal and gastric ulcer with histamine-H2-receptor antagonists].
    Hentschel E
    Wien Med Wochenschr; 1983; 133(4-5):104-7. PubMed ID: 6134397
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.